Researchers from the Fox Chase Cancer Center have found a new use for the hormone hCG, human chorionic gonatropin – preventing breast cancer.
The study used animal models where rats were injected with hCG and exposed to known carcinogens and a control group where there was no hCG injections.
The study used animal models where rats were injected with hCG and exposed to known carcinogens and a control group where there was no hCG injections. The results showed that the rats with the hCG injections were less likely to develop breast cancer than the control group. Also, the rats that were exposed to hCG but did develop breast cancer, did so at a much slower pace. The findings suggest that the hormone makes breast tissue more resistant to cancer.
hCG is a hormone that is commonly used as a fertilization drug and is FDA approved. Human studies are already underway in the US and in Europe.
“The ability to replicate the naturally protective effects of pregnancy against breast cancer will hold a significant public health value,” says Johana Vanegas, M.D., a research associate at Fox Chase. “In order to translate our finding into humans, a clinical trial with hCG as a preventive agent against breast cancer, is already ongoing in pre-menopausal women with no previous pregnancy.”
Researchers Find hCG Fights Breast Cancer
Human chorionic gonadotropin (hCG), a hormone commonly associated with pregnancy, is gaining attention for its potential role in combating breast cancer. Recent studies suggest that hCG may offer protective effects against the development and progression of breast cancer, opening new avenues for research and treatment strategies.
hCG is naturally produced during pregnancy and plays a critical role in supporting fetal development. Researchers have discovered that it may also influence breast tissue by regulating cellular growth and differentiation. These mechanisms appear to inhibit the processes that lead to tumor formation, making hCG a promising candidate for breast cancer prevention and treatment.
One of the key findings is hCG’s ability to promote apoptosis, or programmed cell death, in cancerous cells while sparing healthy tissue. This targeted action reduces the likelihood of side effects compared to conventional chemotherapy. Additionally, hCG’s anti-inflammatory properties may help create an environment less conducive to cancer growth.
While these findings are promising, hCG as a therapeutic option for breast cancer is still in its early stages. Clinical trials are necessary to determine its safety, efficacy, and optimal dosing. Researchers are also exploring how synthetic or modified versions of hCG could enhance its effectiveness in medical applications.
This discovery could revolutionize breast cancer care by offering a natural, hormone-based treatment alternative. However, much work remains to translate these findings into practical therapies. With further investigation, hCG might soon become a powerful tool in the fight against one of the most common cancers affecting women worldwide.
Researchers Find hCG Fights Breast Cancer
